Association Between Serum Uric Acid and Lung Function in People with and without Chronic Obstructive Pulmonary Disease

• Published in: International journal of chronic obstructive pulmonary disease Vol. 17; pp. 1069 - 1080
• Main Authors: Yang, Huajing, Wang, Zihui, Xiao, Shan, Dai, Cuiqiong, Wen, Xiang, Wu, Fan, Peng, Jieqi, Tian, Heshan, Zhou, Yumin, Ran, Pixin
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2022; Dove Medical Press Ltd; Dove; Dove Medical Press
• Subjects: Analysis; Blood tests; Body mass index; Chronic obstructive pulmonary disease; copd; Cross-Sectional Studies; Dyspnea; Forced Expiratory Volume; Humans; Hypoxia; Laboratories; Lung; Lung diseases, Obstructive; lung function; non-copd; Original Research; Population; Pulmonary Disease, Chronic Obstructive - diagnosis; Questionnaires; serum uric acid; Smoking; Spirometry; Tuberculosis; Uric Acid; Values; Vital Capacity; China; serum uric acid; lung function; non-COPD; COPD
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S356797

The effect of serum uric acid (SUA) levels on lung function in chronic obstructive pulmonary disease (COPD) people remained unclear. We aimed to investigate the association between SUA and lung function. A cross-sectional study was performed to measure the SUA levels and lung function in 2797 consecutive eligible individuals. Of these, individuals in our study were divided into two groups, the COPD group (n=1387) and the non-COPD group (n=1410). The diagnosis of COPD is defined as post-bronchodilator first second of forced expiratory volume (FEV )/forced vital capacity (FVC) ratio of less than 0.70. Multivariable adjustment linear models were applied to estimate the effect of SUA levels on FEV % predicted, FVC% predicted, and FEV /FVC stratified by COPD status. After multivariable adjustment, each 1 mg/dL increase of SUA was significantly associated with a decrease in FEV % predicted (-1.63%, 95% confidence interval [CI] -2.37 to -0.90), FVC % predicted (-0.89%, 95% CI -1.55 to -0.24), and FEV /FVC (-0.70%, 95% CI -1.10 to -0.30). In the COPD group, each 1 mg/dL increase of SUA was significantly associated with decreases in FEV % predicted (-1.87%, 95% CI -2.91 to -0.84), FVC% predicted (-1.35%, 95% CI -2.35 to -0.34), and FEV /FVC (-0.63%, 95% CI -1.18 to -0.08). However, no significant association between lung function and SUA was found among people without COPD. High SUA levels were associated with lower lung function, especially in COPD patients. However, no statistically significant effect of SUA on lung function was found in people without COPD.